Inhibikase Says FDA Clears IND For IkT-001Pro To Treat Chronic Myelogenous Leukemia
(RTTNews) - Pharmaceutical company Inhibikase Therapeutics, Inc. (IKT) announced Friday that the U.S. Food and Drug Administration (FDA) has reviewed its Investigational New Drug (IND) application for IkT-001Pro for the treatment of Chronic Myelogenous Leukemia (CML) and issued a Study May Procced (SMP) letter.
IkT-001Pro is a prodrug formulation of imatinib mesylate and has been developed to improve the safety of the first FDA-approved Abelson (Abl) kinase inhibitor, imatinib (marketed as Gleevec).
IkT-001Pro has the potential to be a safer alternative for patients and may improve the number of patients that reach and sustain major and/or complete cytogenetic responses in stable-phase CML.
In preclinical studies, IkT-001Pro was shown to be as much as 3.4 times safer than imatinib in non-human primates, reducing burdensome gastrointestinal side effects that occur following oral administration.
Imatinib delivered as IkT-001Pro was granted Orphan Drug Designation for stable-phase CML in September, 2018.
IkT-001Pro will be evaluated in a single ascending dose bioequivalence study and will enroll approximately 64 male and female healthy volunteers aged 25 to 55 who will receive IkT-001Pro at one of four doses.
For More Such Health News, visit rttnews.com
U.S. Dollar Ticks Lower As Investors Monitor Developments In Middle East
TSX Drops Nearly 2.5%; Materials, Tech Stocks Down Sharply
Swiss Market Ends Modestly Higher
Major European Markets End Mixed As Investors React To Earnings, Economic Data
Chicago Business Barometer Pulls Back But Still Indicates Growth In October
Colgate-Palmolive Q3 Results Rise, Lifts FY26 Base Business EPS View; Stock Gains
Bay Street Likely To Open Notably Lower
